Consultancy services for Life Science companies in the areas of corporate and business development, corporate and commercial strategy planning, implementation and follow-up, market /product potential assessment, and development plans.

Peptonic Medical AB (publ) is an innovative biomedical company that conducts research on and development of drugs and medical devices in the field of women’s health. Our vision is to offer safe and effective treatments for women-specific diseases and medical conditions. Peptonic Medical launched VagiVital® in July 2018. This is a hormone-free product for the treatment of vaginal atrophy and vaginal dryness.The company was founded in 2009 and the share has been traded since 2014 on Spotlight (www.spotlightstockmarket.se, short code: PMED) in Stockholm.Since August 2020, Lune Group Oy Ltd. is a wholly owned subsidiary of the Peptonic Medical Group. Lune Group Oy Ltd.was founded in 2005 by Heli Kurjanen and has earned its place as a top global menstrual cup company through its continued focus on quality, safety, sustainability and inclusivity. Lunetteâ Menstrual Cups are an alternative to disposable period products lasting for several years. The company has resellers in 50 countries and sells Lunetteâ products to over 100 countries via its online store. In the USA, Lune Group has a subsidiary (Lune North America Inc.) Lunetteâ Menstrual Cups are designed, manufactured and packaged in Finland. You can get more information about Lunetteâ by visiting https://se.lunette.com/.

Pharmaprim is a privately owned pharmaceutical company represented across the Nordic region. Our products are primarily prescription pharmaceuticals but we also carry medical devices in our portfolio. In the next few years we expect to launch more products. Our products originate from established foreign companies searching for a successful representation in the Nordic Region. At Pharmaprim we carefully select our products through a rigorous process. We aim at building a competitive portfolio with products in disease areas where there is a great medical need and where synergies can be reached in marketing and sales.Our professional team has a profound Life Science back ground with several successful achievements in their track record. Our key competencies are within Marketing, Sales and Business Development. We have high standards on safety, documentation and quality for our products.Pharmaprim has integrated partnerships with Nordic professional service providers within logistics, regulatory affairs, health economics and safety monitoring.

Overall responsibility for global product search and in-licensing of for the Nordic markets. Joint planning and execution of M&A activities with CEO and Corporate Development department.Achievements:Planned, lead and concluded the negotiations leading to the license and distribution agreement between Medivir and Ferrer Internacional S.A. in September 2013, granting Medivir the commercial rights to ADASUVE® (a psychiatry drug) in the Nordic region. Planned, lead and concluded the negotiations leading to the buy-out agreement between Medivir and Meda regarding the commercial rights of Xerese™ in North America (USA, Canada and Mexico) on June 29th, 2011. Deal value: USD 45 million, plus USD 10 million in regulatory milestone and royalty on sales of future new products developed by Meda.Planned, lead and concluded the negotiations leading to the closure of a licensing agreement between Medivir and;- Meda regarding the commercialization of Xerese™ in North America on Feb 15th, 2010. Deal value: Upfront USD 5 million, double-digit royalty on sales.- GlaxoSmithKline (GSK) regarding the commercialization of Xerclear™ in Europe and several key markets incl. India, Japan, Russia, Australia on June 22nd, 2010. Deal value: Upfront+milestones Euro 3 million, double-digit royalty on sales.- Daewoong Pharmaceutical Co Ltd regarding the commercialization of Xerclear™ in South Korea on August 22nd, 2010. Deal value: not disclosed.- Luxembourg Pharmaceutical Ltd regarding the commercialization of Xerclear™ in Israel and the Palestinian Authority on September 28th, 2010. Deal value: not disclosed.- Daewoong Pharmaceutical Co Ltd regarding the commercialization of Xerclear™ in China and Hong Kong on June 23rd, 2011. Deal value: not disclosed.Member of the core team at Medivir responsible for consummating the acquisition of BioPhausia by Medivir in June 2011. Transaction value: SEK 550 million (EUR 60 million).

Overall responsibility for global partnering/out-licensing of Xerese/Xerclear - Medivir's cold sore drug. In-licensing/acquisition of products for the Nordic markets. Joint planning and execution of M&A activities with CEO and Corporate Development department.

Overall responsibility for building up a Marketing and Sales organisation and to productify Vironova's diagnoistic services and products, including out-licensing of the image analysis technology. Head of Communications and Member of the Management Team. Fund raising together with the company's CEO and CFO.Main responsibilities included planning and execution of the marketing and sales activities of the virus diagnostics software and image analysis services developed in-house, managing the sales team, develop distribution networks and channels, planning new product launches, establish pricing policies, production of marketing and sales material, visiting customers and partners, and key account management. Additional responsibilities included various Business Development assignments such as planning and preparing for exiting/partnering the drug development projects, evaluation of new project proposals (internal and external), and Head of Communications.Member of the Management Team.AchievementsIn-licensing of anti-viral drug development project from Univ. of Maryland (USA).Established sales and marketing team for image analysis services. Initiated sales which reached approx. SEK 1 million the first year.

Overall responsible for out-licensing Innoventus's clinical projects (portfolio consisted of 5 drug development projects, 2 medical device projects and 1 bio-flourecense project). Member of the Management team.

Overall responsible for the company's business development aactivities including key account management (KAM) of the largest key accounts i.e. Cordis (JnJ), Medtronic, and W.L. Gore. Out-licensing of Carmedas MACHS technology. Actively involved in the divestment transaction of the company together with CEO and chief financial officer. Member of the Management team.

Assisting the HealthCap portfolio companies with business and corporate development activities. Assessment of investment cases.

A biotech R&D company with own (GMP –ready) manufacturing of astaxanthin – a new and unique antioxidant for use in humans and animals (Drug development indications: fertility enhancement, endurance enhancement and GI infections/diseases). B2B and B2C sales of dietary supplements and veterinary/animal feed products through own subsidiary and distributor network.

Direct reporting to the CEO of this biotech R&D company with own (GMP –ready) manufacturing of astaxanthin – a new and unique antioxidant for use in humans and animals (Drug development indications: fertility enhancement, endurance enhancement and GI infections/diseases). B2B and B2C sales of dietary supplements and veterinary/animal feed products through own subsidiary and distributor network. Member of the Management team.

Overall responsiblilty for marketing and sales of Finnfeeds International Ltd (Cultor Ltd) feed additives (enzymes, betaine) in Germany.

Overall responsibility for FFI Ltd's R&D. Territorial marketing and sales responsibility in South East Asia (incl. Australia and New Zealand).

Technician to Dr Vemmer in a project concerning the carry-over effect of heavy metals (Cd) in the diet to animal tissue, using the rat as a model.